{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:18:48Z","timestamp":1787635128198,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is an antibody-mediated autoimmune neuromuscular disorder for which long-term disease control remains challenging in some patients. Telitacicept, a dual inhibitor of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), has been investigated as a potential therapeutic option for MG. This systematic review aimed to evaluate the clinical efficacy, steroid-sparing effects, and safety profile of telitacicept in patients with MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Scopus, Web of Science Core Collection, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), and Wanfang Data was conducted from database inception to January 19, 2026. Studies reporting clinical outcomes of telitacicept in MG were included. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment. Due to substantial heterogeneity in study designs, patient populations, treatment strategies, and outcome measures, a qualitative synthesis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies, including one randomized phase II trial, four retrospective cohort studies, one retrospective comparative study, four case series, and five case reports, were included. Available evidence generally suggested improvements in disease severity measures, particularly reductions in Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. In the randomized phase II trial of generalized MG, QMG decreased by approximately 7\u201310 points at 24 weeks, with response rates exceeding 90%. Several observational studies also reported reductions in glucocorticoid requirements. Adverse events were generally mild and transient, although the interpretation of long-term safety was limited by small sample sizes and short follow-up durations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Current evidence suggests that telitacicept may provide potential clinical benefits and steroid-sparing effects in selected patients with MG. However, the certainty of evidence remains limited because most available studies were retrospective or uncontrolled, and further well-designed randomized controlled trials are required to establish its efficacy, long-term safety, and optimal clinical positioning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1916224","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:23:27Z","timestamp":1787631807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Telitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safety"],"prefix":"10.3389","volume":"17","author":[{"given":"Weitong","family":"Zhang","sequence":"first","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Qiao","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3389\/fimmu.2020.01688","article-title":"Editorial: advances in autoimmune myasthenia gravis","volume":"11","author":"Punga","year":"2020","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.3390\/jcm15072488","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis, the impact of different administration routes on bone mineral density, and fracture risk and treatment options-a narrative review","volume":"15","author":"Kapszewicz","year":"2026","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"101970","DOI":"10.1016\/j.disamonth.2025.101970","article-title":"A comprehensive review of the treatment options in myasthenia gravis","volume":"71","author":"Randall","year":"2025","journal-title":"Dis Mon"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e179742","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a Focussed review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"104042","DOI":"10.1016\/j.autrev.2026.104042","article-title":"The BAFF\/APRIL system at the crossroads of B cell memory and autoimmune relapse: implication into the therapeutic strategies","volume":"25","author":"Liao","year":"2026","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40258-024-00897-x","article-title":"Predictors of high healthcare cost among patients with generalized myasthenia gravis: a combined machine learning and regression approach from a US payer perspective","volume":"22","author":"Zhdanava","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of Telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1549034","DOI":"10.3389\/fimmu.2025.1549034","article-title":"Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.2147\/JIR.S513986","article-title":"Efgartigimod followed by Telitacicept in adult generalized myasthenia gravis: a retrospective case series","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflamm Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"17562864241251476","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","article-title":"A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis","volume":"31","author":"Yin","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3969\/j.issn.1672-3384.2025.12.005","article-title":"Efficacy of telitacicept combined with conventional immunotherapy in myasthenia gravis: a retrospective cohort study","volume":"23","author":"Lu","year":"2025","journal-title":"Clin Med J"},{"key":"ref29","volume-title":"Clinical Efficacy and Safety of B-cell indirect Immune-Targeted agent Telitacicept in the Treatment of Myasthenia Gravis","author":"Dou","year":"2025"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11481-025-10272-9","article-title":"Telitacicept as a new therapeutic avenue for generalized myasthenia gravis and thymoma-associated myasthenia gravis","volume":"21","author":"Zhu","year":"2026","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e71157","DOI":"10.1002\/brb3.71157","article-title":"Add-on Telitacicept significantly improves outcome of patients with refractory ocular myasthenia gravis a real-world case series","volume":"16","author":"Lin","year":"2026","journal-title":"Brain Behav"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3969\/j.issn.1673-5501.2025.04.006","article-title":"Ocular myasthenia gravis treated with telitacicept in 4 children: a case series report","volume":"20","author":"Mao","year":"2025","journal-title":"Chin J Evid Based Pediatr"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1501500","DOI":"10.3389\/fneur.2025.1501500","article-title":"Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review","volume":"16","author":"Song","year":"2025","journal-title":"Front Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1552521","DOI":"10.3389\/fimmu.2025.1552521","article-title":"Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"rxaf074","DOI":"10.1093\/mrcr\/rxaf074","article-title":"Successful treatment of rheumatoid arthritis complicated with myasthenia gravis by telitacicept: a case report","volume":"9","author":"Qiu","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1456822","DOI":"10.3389\/fimmu.2024.1456822","article-title":"Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1400459","DOI":"10.3389\/fimmu.2024.1400459","article-title":"Case report: a highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00415-023-12036-y","article-title":"Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/nejmra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1916224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:23:29Z","timestamp":1787631809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1916224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":40,"alternative-id":["10.3389\/fneur.2026.1916224"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1916224","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1916224"}}